![Henrik Stage](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Henrik Stage
Plus aucun poste en cours
Profil
Henrik Stage is the founder of Skape Bio ApS, founded in 2025, holding the title of Director.
Mr. Stage was the founder of ADCendo ApS, founded in 2017, holding the title of Chief Financial Officer from 2021 to 2022.
Stage is also the founder of Fuse Vectors ApS..
Mr. Stage is currently Chairman at Biomia ApS since 2022.
Stage is currently Director at ResoTher Pharma AS.
Stage is currently Director at iNotify ApS.
Stage is currently Partner at Ventac Partners A. Mr. Stage is currently Owner at Next Stage Ventures ApS.
Formerly, Mr. Stage was Chief Executive Officer at RICC A from 2012 to 2014.
Stage was Chief Financial Officer at SynAct Pharma AB from 2016 to 2022.
Stage was Chief Financial Officer at RhoVac AB. Stage completed graduate education at Copenhagen Business School.
Postes actifs de Henrik Stage
| Sociétés | Poste | Début |
|---|---|---|
Ventac Partners A/S
 Ventac Partners A/S Miscellaneous Commercial ServicesCommercial Services Provides life science consulting services | Corporate Officer/Principal | - |
ResoTher Pharma AS
 ResoTher Pharma AS Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops peptide-based drugs | Directeur/Membre du Conseil | - |
Next Stage Ventures ApS
 Next Stage Ventures ApS Miscellaneous Commercial ServicesCommercial Services Engages in research and development of biotechnology products | Corporate Officer/Principal | - |
Anciens postes connus de Henrik Stage
| Sociétés | Poste | Fin |
|---|---|---|
ADCendo ApS
 ADCendo ApS BiotechnologyHealth Technology Operates as a clinical-stage biotech company that dedicated to developing transformative first and best-in-class antibody-drug conjugate therapies for cancers | Directeur Général | 07/07/2021 |
| SYNACT PHARMA AB | Directeur Financier/CFO | 07/01/2022 |
| CHOSA ONCOLOGY AB | Directeur Financier/CFO | - |
Roche Innovation Center Copenhagen A/S
 Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases | Directeur Général | 09/01/2014 |
Formation de Henrik Stage
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
5
Relations au 1er degré
8
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
Copenhagen Business School
 Copenhagen Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Roche Innovation Center Copenhagen A/S
Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases | Health Technology |
SynAct Pharma AB
 SynAct Pharma AB Pharmaceuticals: MajorHealth Technology Provides pharmaceutical drugs for treatment inflammatory diseases | Health Technology |
Ventac Partners A/S
Ventac Partners A/S Miscellaneous Commercial ServicesCommercial Services Provides life science consulting services | Commercial Services |
RhoVac AB
 RhoVac AB BiotechnologyHealth Technology Engages in the research and development of immunotherapy for therapeutic cancer vaccines | Health Technology |
Next Stage Ventures ApS
Next Stage Ventures ApS Miscellaneous Commercial ServicesCommercial Services Engages in research and development of biotechnology products | Commercial Services |
ResoTher Pharma AS
ResoTher Pharma AS Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops peptide-based drugs | Health Technology |
ADCendo ApS
ADCendo ApS BiotechnologyHealth Technology Operates as a clinical-stage biotech company that dedicated to developing transformative first and best-in-class antibody-drug conjugate therapies for cancers | Health Technology |
